Crossmark

Ly6D+Siglec-H+ precursors contribute to conventional dendritic cells via a Zbtb46+Ly6D+ intermediary stage

Crossref DOI link: https://doi.org/10.1038/s41467-022-31054-4

Published Online: 2022-06-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lutz, Konstantin https://orcid.org/0000-0002-6263-467X
Musumeci, Andrea https://orcid.org/0000-0002-2497-0699
Sie, Christopher https://orcid.org/0000-0002-8066-7539
Dursun, Ezgi

Winheim, Elena https://orcid.org/0000-0002-0364-662X
Bagnoli, Johannes

Ziegenhain, Christoph https://orcid.org/0000-0003-2208-4877
Rausch, Lisa

Bergen, Volker https://orcid.org/0000-0003-2486-1473
Luecken, Malte D. https://orcid.org/0000-0001-7464-7921
Oostendorp, Robert A. J. https://orcid.org/0000-0002-4947-0412
Schraml, Barbara U. https://orcid.org/0000-0002-5801-0151
Theis, Fabian J. https://orcid.org/0000-0002-2419-1943
Enard, Wolfgang https://orcid.org/0000-0002-4056-0550
Korn, Thomas https://orcid.org/0000-0002-3633-0955
Krug, Anne B. https://orcid.org/0000-0002-9556-7207
Funding

Funding for this research was provided by:

Friedrich-Baur-Stiftung

Deutsche Forschungsgemeinschaft (278529602-SFB1243-A09)

Deutsche Forschungsgemeinschaft (360372040–SFB 1335-P08)

Deutsche Forschungsgemeinschaft (322359157-FOR2599-A03)

Deutsche Forschungsgemeinschaft (278529602-SFB 1243-A14)

Deutsche Forschungsgemeinschaft (210592381-SFB 1054-B06)

Deutsche Forschungsgemeinschaft (408885537-TRR 274-A01)

Deutsche Forschungsgemeinschaft (390857198-EXC 2145)

Deutsche Forschungsgemeinschaft (213904703-TRR 128-A07)

Deutsche Forschungsgemeinschaft (210592381-SFB 1054-A06)

Deutsche Forschungsgemeinschaft (369799452-SFB/TRR 237-B14)

Deutsche Forschungsgemeinschaft (391217598-KR2199/10-1)

Helmholtz Association (Helmholtz AI ZT-I-PF-5-01)
License Information

Text and Data Mining valid from 2022-06-16

Version of Record valid from 2022-06-16
More Information

Article History

Received: 8 March 2021

Accepted: 24 May 2022

First Online: 16 June 2022

Competing interests

: F.J.T. reports receiving consulting fees from Roche Diagnostics GmbH, Immunai Inc., Singularity Bio B.V., CytoReason Ltd, and Omniscope Ltd Inc., and has an ownership interest in Cellarity, Inc. and Dermagnostix GmbH. VB is a full-time employee of Cellarity Inc. and reports ownership interest in Cellarity Inc.; the present work was carried out at Helmholtz Munich. The other authors declare no competing interests.

Document is current

Any future updates will be listed below